Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s Ministry Of Health To Issue Concrete Measures On Public Hospital Reform Pilot

This article was originally published in PharmAsia News

Executive Summary

At a recent China Ministry of Health press conference, spokesman Mao Qunan said the MOH and other relevant ministries will first conduct pilot programs on the complicated public hospital reform plan and draw conclusions from their experiences before undertaking widespread implementation. He pointed out that the hospital reform will involve the entire structure, ranging from hospital management and internal operations to economic policies. Pilots will be undertaken in certain regions instead of merely by some hospitals to try out the reform plan on a systems level. Surveys show health care administration and medical personnel pay close attention to the reform, thus the pilot's success depends very much on their active participation. (Click here for more - Chinese language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070784

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel